['hepatitis c virus infection']
['ldv/sof', 'rbv']

        Key Inclusion Criteria:

          -  Participants who failed treatment in Study GS-US-334-0119 who meet relevant
             inclusion/exclusion criteria are eligible for retreatment in this study

          -  Chronic genotype 1 HCV infection

          -  HCV treatment-naive

          -  HCV RNA > 10,000 IU/mL at screening

          -  Absence of cirrhosis

          -  Screening laboratory values within defined thresholds

          -  Use of two effective contraception methods if female of childbearing potential or
             sexually active male

        Key Exclusion Criteria:

          -  Pregnant or nursing female or male with pregnant female partner

          -  Infection with hepatitis B virus (HBV)

          -  Current or prior history of clinical hepatic decompensation

          -  Chronic use of systemic immunosuppressive agents

          -  History of clinically significant illness or any other medical disorder that may
             interfere with the individual's treatment, assessment, or compliance with the protocol

          -  For HIV-1/HCV co-infected individuals:

               -  Opportunistic infection within 6 months prior to screening

               -  Active, serious infection (other than HIV-1 or HCV) requiring parental
                  antibiotics, antivirals or antifungals within 30 days prior to baseline

               -  Treatment with an antiretroviral (ARV) regimen other than one of those listed in
                  the study protocol

        Note: Other protocol defined Inclusion/Exclusion criteria may apply.
      